News
At Argent BioPharma, our mission is to revolutionize healthcare through pioneering innovation.
We go beyond traditional disease management by exploring the intricacies of the immune system and harnessing cutting-edge technologies in our research and development endeavors.
Through our commitment to advancing medical science, we aim to reshape the landscape of global healthcare by addressing unmet needs and offering hope to underserved populations worldwide.
Our vision encompasses becoming a leading biopharmaceutical company renowned for groundbreaking medical treatments. By embracing NanoPolyPharmacology, we strive to introduce impactful solutions that elevate standards within the life sciences industry. Our dedication extends to ensuring accessibility to innovative therapies for communities overlooked by conventional medical approaches, thereby bridging healthcare disparities on a global scale.
As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we’re not just changing treatments; we’re changing lives.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
Health & Biotech
MGC Pharma granted approval in Slovenia to manufacture and conduct research into the burgeoning space of psychedelics
Experts
MoneyTalks: Two biotechs and a fitness stock that are set to blast off, according to brokers
News
Rise and Shine: Everything you need to know before the ASX opens
News
CLOSING BELL: $35 billion in sweet, sweet divvies suddenly makes it all seem worthwhile
Health & Biotech
ASX Health Stocks: Firebrick to start Phase 3 trial on common cold spray, MGC Pharma surges 30pc on FDA listing
Health & Biotech
A huge leap for MGC Pharma as Covid-19 spray ArtemiC is included in the FDA’s National Drug Code Database
News
Top 10 at 10: Which gold junior is up 120pc after signing a US$300m funding facility?
Health & Biotech
Weed Week: BOD advances Aqua Phase acquisition with stability testing
Health & Biotech
ASX Health Stocks: Emyria partners with Pax Centre to provide psychedelics therapy for PTSD sufferers
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
News
Market Highlights: ASX to kick off 2023 on a high note, and 5 small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: NSB files patent in Australia, Cronos ships one-millionth medicinal cannabis unit
News
Market Highlights: Blowout US jobs data, OPEC’s call, and 5 ASX small caps to watch on Monday
Health & Biotech
ASX Biotech Stocks: Estia picks up 4 new aged care homes; MGC flags positive result for long COVID symptoms
News
Rise and Shine: Everything you need to know before the ASX opens
News